HK/China Healthcare Analyst (ex-Fosun Pharma)

Xinyao (Criss) Wang

Over 15 years' experience in both finance and healthcare, covering clinic operations, investment and equity research in both China and overseas.

Aier Eye Hospital Group (300015.CH) - More than Just Bribery Scandal

China Healthcare Weekly (Jan.21)-Growth Hormone VBP,Biotech Survival,Internationalization Conditions

Pre-IPO Remegen Co Ltd - Some Points Worth the Attention

The Concerns and Outlook About the Recent Rally in Traditional Chinese Medicine (TCM) Sector

Concerns and Outlook on China Neuro-Interventional Industry

The CXO/Biotech Plunge and the Afterwards Investment Logic (2022)

Gravity Works As WeWork Doesn't; Now Plan B

Thematic (Sector/Industry)

Hong kong Healthcare equipment and services / Thematic (Sector/Industry)

<ul>
<li>Last week, we saw some rebounds in the healthcare sector, and many investors begin to believe that a complete reversal is imminent. </li>
<li>Our view is that this is <strong>a temporary rebound</strong> after continuous pull-back due to the broken logic, rather than <strong>a complete reversal</strong>.We recommend investors to see the rebound rationally.</li>
<li>In terms of the future direction of stock price, we analyze it based on three scenarios.</li>
</ul>


Last week, we saw some rebounds in the healthcare sector, and many investors begin to believe that a complete reversal is imminent. 
Our view is that this is a temporary rebound after continuous pull-back due to the broken logic, rather than a complete reversal.We recommend investors to see the rebound rationally.
In terms of the future direction of stock price, we analyze it based on three scenarios.


The Insecure Rebound in Healthcare Sector and the Future Direction of Stock Price (2022)